BRITISH drugmaker GlaxoSmithKline (GSK) today announced the purchase of Canadian chronic cough treatment specialist Bellus for US$2 billion (RM8.84 billion).
It comes after GSK, led by chief executive Emma Walmsley, demerged its consumer healthcare unit Haleon last year, leaving the group to focus on drugs.